Gene technology-focused Qihan Biotech on Monday said it has bagged as much as $67 million in its Series A++ round from a slew of investors.
Lilly Asia Ventures and Matrix Partners China were the new investors in the round while return backers Sequoia Capital China and state-backed China Merchants Group’s Hong Kong-based arm CMB International made a follow-on investment.
